Dr Pietrantonio: Yes. We will see important results. ASCO was a very good meeting in 2024 for gastric cancer patients. There are new trials， for example， the RENAISSANCE trial done in Europe in Germany in patients with limited-metastatic disease. The treatment paradigm is rapidly changing. We have neoadjuvant immunotherapy， and other important trials. The Plenary Session was just concluded and the ESOPEC phase Ⅲ trial results were presented. This trial compared FLOT versus CROSS in patients with esophageal adenocarcinoma， and that trial is positive for an overall survival benefit with FLOT chemotherapy， so the long debate about the best treatment option in this disease is maybe finally over with FLOT as the winner.
美国罗克维尔和中国苏州2022年10月31日 /美通社/ -- 信达生物制药集团，一家致力于研发、生产和销售肿瘤、自免、代谢、眼科等重大疾病领域创新药物的生物制药公司，今日宣布其重组人源抗紧密连接蛋白18.2抗体药物偶联物在澳大利亚进行的I期临床试验中完成首例受试者给药。
新京报讯（记者王卡拉）9月2日，步长制药发布公告，控股子公司四川泸州步长生物制药在研1类新药“注射用BC001”新增适应症的临床试验申请获国家药监局批准，拟开展适应症为BC001联合普特利单抗治疗晚期实体瘤，包括但不限于BC001和普特利单抗联合化疗（卡培他滨和奥沙利铂）一线治疗
参考文献:1.Randon G， Nappo F， Fassan M， et al. Switch maintenance with ramucirumab plus paclitaxel versus continuation of oxaliplatin-based chemotherapy in advanced HER2-negative gastric or gastroesophageal junction cancer: final results and key biomarkers of the ARMANI phase III trial. Presented at: 2024 ESMO Gastrointestinal Cancers Congress;
新京报讯（记者张兆慧）8月15日，步长制药发布公告称，控股子公司泸州步长拟与俄罗斯公司LANCET签署《经销和许可协议》，泸州步长拟许可LANCET在欧亚经济联盟（俄罗斯、白俄罗斯、哈萨克斯坦、亚美尼亚、吉尔吉斯斯坦）和乌兹别克斯坦内，就注射用BC001作为产品上市许可的持有人进
